top of page

Translating fundamental immunology into industrially as well as clinically scalable next-generation immunotherapies and precision biomarkers

At the CSI Lab, we believe that scientific discoveries achieve their greatest value when they transcend academic boundaries and create tangible benefits for patients and society. Valorization and innovation are therefore integral to our research philosophy, connecting fundamental discoveries in cellular stress, cancer immunology and immune resistance with intellectual property development, industrial partnerships, clinical investigation and future commercialization opportunities. Our patient-centred, reverse-translational approach combines human multi-omics and spatial immunology, artificial intelligence, systems medicine and functional experimentation to identify clinically relevant immune mechanisms and actionable therapeutic vulnerabilities. We aim to transform these insights into precision biomarkers, novel antibody-based immunotherapies, advanced cancer vaccines and rational therapeutic combinations, particularly for hard-to-treat and immunotherapy-refractory cancers.

One major step toward this ambition is our collaboration with PharmAbs – the KU Leuven Antibody Centre (click here for the website), where Prof. Abhishek D. Garg has joined as board member. This partnership connects our expertise in systems immunology and AI-driven target discovery with PharmAbs' capabilities in antibody/nanobody discovery, engineering and biotherapeutic development. Together, we are pursuing next-generation multispecific antibodies designed to overcome complex, interconnected mechanisms of tumour immune resistance, creating opportunities for intellectual property development and industrial co-development.

Complementing this partnership, we have established RETROFIT (REverse TRanslatiOn For multi-specific ImmunoTherapy), an innovative lab-in-the-loop platform designed to accelerate the discovery and development of next-generation or first-in-class immunotherapies (click here for the website). RETROFIT integrates large-scale human and preclinical single-cell, spatial and bulk omics datasets, "causality-friendly" AI-driven systems analysis, rational multispecific antibody engineering and lab-in-the-loop functional validation to identify promising therapeutic targets and advance novel immunotherapeutic candidates toward preclinical development and potential clinical translation. This is accompanied by development of digital pathology-based companion biomarkers for patient pre-selection and appropriate therapy positioning (see Figure below for an overview of RETROFIT platform's groundbreaking design).

These activities build upon our broader translational achievements, including the sFIS blood-based immunomonitoring biomarker, AI-driven precision immune signatures and next-generation dendritic cell vaccination strategies undergoing clinical investigation (see "To the clinic" tab for for details). Our long-term vision is to establish a sustainable discovery-to-impact ecosystem that brings together academia, clinicians, biotechnology and pharmaceutical partners. Through patents, technology licensing, collaborative development, clinical trials and potential future spin-offs, we aim to accelerate the journey from mechanistic discovery to clinically meaningful innovation.

Our RETROFIT platform is currently advancing a pipeline of first-in-class multi-specific antibodies across multiple stages of preclinical development, with the potential to treat a broad range of solid tumor indications and to extend into additional disease areas beyond oncology (see Figure below).

Here, our lead asset i.e., RF-001 (an investigational, first-in-class tri-specific antibody engineered to selectively target the newly discovered tumor-specific macrophages that co-expresses TIM3, VISTA and CSF1R; Vanmeerbeek et al., Science Adv 2024) is currently in advanced stages of lead optimization and part of a developing patent family consisting of the following patent applications:
1. A biomarker patent on TIM3+VISTA+CSF1R+TAMs: click here for WO2025093579!
2. A therapeutic proof-of-concept patent on preclinical prototype of RF-001: click here for WO2025238157!

  • KU Leuven
  • Department of Cellular & Molecular Medicine
  • X
  • LinkedIn
  • download
  • bluesky

© 2025 by Prof. Abhishek D. Garg. Ceated with Wix.com

bottom of page